Abstract
This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.
Udgivelsesdato: 2009-May-4
Udgivelsesdato: 2009-May-4
Bidragets oversatte titel | Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for læger |
Vol/bind | 171 |
Udgave nummer | 19 |
Sider (fra-til) | 1598-602 |
Antal sider | 4 |
ISSN | 0041-5782 |
Status | Udgivet - 2009 |